PharmaShots | Incisive News in 3 Shots

Subscribe Now

VLA15

Valneva and Pfizer Present P-II (VLA15-221) Study Data of VLA15 Vaccine for Lyme Disease

Valneva and Pfizer Present P-II (VLA15-221) Study Data of VLA15 Vaccine for Lyme Disease

September 3, 2024

Valneva and Pfizer Report P-II Study (VLA15-221) Results of VLA15 for Lyme Disease in Pediatric and Adolescent

Valneva and Pfizer Report P-II Study (VLA15-221) Results of VLA15 for Lyme Disease in Pediatric and Adolescent

September 7, 2023

Pfizer and Valneva Report Partial Discontinuation of Patient Evaluation in P-III Clinical Trial for VLA15 to Treat Lyme Disease

Pfizer and Valneva Report Partial Discontinuation of Patient Evaluation in P-III Clinical Trial for VLA15 to Treat Lyme Disease

February 20, 2023

Valneva and Pfizer Report Results of VLA15 in P-II (VLA15-221) Trial for the Treatment of Lyme Disease

Valneva and Pfizer Report Results of VLA15 in P-II (VLA15-221) Trial for the Treatment of Lyme Disease

April 26, 2022

Pfizer and Valneva Report Results of VLA15 in P-II Study for the Treatment of Lyme Disease

Pfizer and Valneva Report Results of VLA15 in P-II Study for the Treatment of Lyme Disease

February 7, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us